ELC Group expands in India with new Mumbai office
This article was originally published in SRA
UK-based pharmaceutical regulatory affairs organisation ELC Group has expanded its presence in India by opening a new office in Mumbai1.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib
Priority review is likely in the US for Kite’s second CAR-T therapy offering but it seems the company will have to make do with standard review in the EU.